<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "../../nlm/tax-treatment-NS0.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:tp="http://www.plazi.org/taxpub" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">87</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:A116C711-4C18-5A38-8F1E-5E97753A8A64</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Folia Medica</journal-title>
        <abbrev-journal-title xml:lang="en">FM</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0204-8043</issn>
      <issn pub-type="epub">1314-2143</issn>
      <publisher>
        <publisher-name>Plovdiv Medical University</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/folmed.66.e104433</article-id>
      <article-id pub-id-type="publisher-id">104433</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Pulmonology</subject>
          <subject>Thoracic surgery</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A giant synovial sarcoma of the left lung</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Yankov</surname>
            <given-names>Georgi</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0003-2068-5724</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Alexieva</surname>
            <given-names>Magdalena</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0000-0003-3884-3057</uri>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Ivanova</surname>
            <given-names>Silvia</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Yankova</surname>
            <given-names>Stefka</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Mekov</surname>
            <given-names>Evgeni</given-names>
          </name>
          <email xlink:type="simple">evgeni.mekov@gmail.com</email>
          <uri content-type="orcid">https://orcid.org/0000-0002-4410-6515</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Department of Respiratory Diseases, St Ivan Rilski University Hospital, Medical University of Sofia, Sofia, Bulgaria</addr-line>
        <institution>Medical University of Sofia</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line content-type="verbatim">St Sofia MHAT, Sofia, Bulgaria</addr-line>
        <institution>St Sofia MHAT</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <aff id="A3">
        <label>3</label>
        <addr-line content-type="verbatim">St Ivan Rilski University Hospital, Sofia, Bulgaria</addr-line>
        <institution>St Ivan Rilski University Hospital</institution>
        <addr-line content-type="city">Sofia</addr-line>
        <country>Bulgaria</country>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding author: Evgeni Mekov, Department of Respiratory Diseases, St Ivan Rilski University Hospital, Medical University of Sofia, Sofia, Bulgaria; Email: <email xlink:type="simple">evgeni.mekov@gmail.com</email>; Tel.: +359 888 320 476</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2024</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>04</month>
        <year>2024</year>
      </pub-date>
      <volume>66</volume>
      <issue>2</issue>
      <fpage>277</fpage>
      <lpage>281</lpage>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/0892E129-98AA-57B3-A494-BDD671791696">0892E129-98AA-57B3-A494-BDD671791696</uri>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>04</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>06</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Georgi Yankov, Magdalena Alexieva, Silvia Ivanova, Stefka Yankova, Evgeni Mekov</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p>Primary pulmonary synovial sarcoma is an extremely rare and aggressive neoplasm that primarily affects young people and has a poor prognosis. Establishing this diagnosis requires the exclusion of a wide number of other neoplasms with multimodal clinical, imaging, histological, immunohistochemical, and cytogenetic assessment. We present a case of synovial sarcoma of the left lung in a 44-year-old man, diagnosed immunohistochemically after left lower lobectomy with atypical resection of the 5th segment. Imaging, diagnostic workup, histological and immunohistochemical characteristics, surgical treatment, and prognosis are discussed.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>diagnostic imaging</kwd>
        <kwd>lung</kwd>
        <kwd>immunohistochemistry</kwd>
        <kwd>synovial sarcoma</kwd>
        <kwd>surgical treatment</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="SECID0EOE">
        <title>Citation</title>
        <p>Yankov G, Alexieva M, Ivanova S, Yankova S, Mekov E. A giant synovial sarcoma of the left lung. Folia Med (Plovdiv) 2024;66(2):277-281. doi: <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3897/folmed.66.e104433">10.3897/folmed.66.e104433</ext-link>.</p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="Introduction" id="SECID0E1E">
      <title>Introduction</title>
      <p>The majority of malignant lung tumors are of epithelial origin. Soft tissue tumors are far less common. Primary lung sarcoma is a rare and aggressive malignancy and lung metastases from extrapulmonary sarcomas are significantly more common than primary pulmonary synovial sarcoma (<abbrev xlink:title="primary pulmonary synovial sarcoma" id="ABBRID0EAF">PPSS</abbrev>).</p>
      <p>Because most mesenchymal malignancies have a benign analogue and certain epithelial tumors show sarcomatoid differentiation (e.g., renal cell carcinoma, melanoma), accurate histological diagnosis, including assessment of the size of the lesion, is critical.<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup></p>
      <p>We present a case of synovial sarcoma of the left lung in a 44-year-old man, diagnosed immunohistochemically after left lower lobectomy with atypical resection of the 5th segment.</p>
    </sec>
    <sec sec-type="Case report" id="SECID0ENF">
      <title>Case report</title>
      <p>
        <italic>A 44-year-old male was admitted to the Department of Thoracic Surgery with pain in the back and the lateral part of the chest wall on the left, fatigue, and cough with mild hemoptysis for a month. He was a smoker and heavy drinker (100 ml daily). Physical examination was remarkable for decreased breath sounds on the left. The laboratory tests, pulmonary function tests, and arterial blood gas analysis showed no abnormalities.</italic>
      </p>
      <p><italic>On chest X-ray, a large heterogeneous mass in the left lower hemithorax was visualized. The computed tomography (<abbrev xlink:title="computed tomography" id="ABBRID0EZF">CT</abbrev>) shows an ovoid lesion of 69×105×90 mm with heterodense structure up to 56 HE in the left lower lung with numerous gas deposits in the matrix, which was widely adhered to the chest wall without infiltrating it but with radicular and reticular interstitial changes around the lesion</italic><bold><italic>(Fig. <xref ref-type="fig" rid="F1">1</xref>)</italic></bold> .</p>
      <fig id="F1" position="float" orientation="portrait">
        <object-id content-type="arpha">BEDAB50D-8ED3-5E2A-87CB-750579862997</object-id>
        <label>Figure 1.</label>
        <caption>
          <p>Axial and coronal <abbrev xlink:title="computed tomography" id="ABBRID0E6HAC">CT</abbrev> images, visualizing left lower lobe synovial sarcoma.</p>
        </caption>
        <graphic xlink:href="foliamedica-66-2-e104433-g001.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_1040211.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1040211</uri>
        </graphic>
      </fig>
      <p>
        <italic>Fibrobronchoscopy (<abbrev xlink:title="Fibrobronchoscopy">FBS</abbrev>) showed a deformed B8 segment with submucosal proliferation but was not diagnostic.</italic>
      </p>
      <p><italic>The surgical approach was through a left lateral thoracotomy in the 5th intercostal space</italic><bold><italic>(Fig. <xref ref-type="fig" rid="F2">2</xref>)</italic></bold> . <italic>A left lower lobectomy with atypical resection of the 5th segment, due to the proximity of the tumor to the major fissure, was performed. In the left lower lobe, a moderately dense tumor lesion of 100×70 mm was found. There was a presence of visibly pathological lymph nodes in the hilum and the pulmonary ligament, the first being located as a cuff around the hilum of the lower lobe. Thorough lymph dissection was performed at levels 5, 7, 9, and 10.</italic></p>
      <fig id="F2" position="float" orientation="portrait">
        <object-id content-type="arpha">85067522-E2D8-5CDB-90B6-8DEA1906AC72</object-id>
        <label>Figure 2.</label>
        <caption>
          <p>Intraoperative image of lateral muscle-sparing thoracotomy in the 5th intercostal space after left lower lobectomy and an atypical resection of the 5th segment.</p>
        </caption>
        <graphic xlink:href="foliamedica-66-2-e104433-g002.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_1040212.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1040212</uri>
        </graphic>
      </fig>
      <p><italic>The specimen dissection showed cavitary tumor lesion which was filled with blood, and a large coagulum</italic><bold><italic>(Fig. <xref ref-type="fig" rid="F3">3</xref>)</italic></bold> . <italic>A pathohistological study demonstrated destruction of the lung parenchyma by tumor tissue (over 100 mm), represented by bundles of monotonous atypical spindle cells, focal myxoid stromal changes, areas of hemorrhages, extensive areas of necrosis, areas of cystic degeneration, and mitoses. The morphological finding refers to malignant intrapulmonary mesenchymal neoplasm. The bronchial stump margin was free of tumor infiltration. Seventeen lymph nodes were examined and all of them were without metastases.</italic></p>
      <fig id="F3" position="float" orientation="portrait">
        <object-id content-type="arpha">441BAB8D-C7C9-5578-9051-D77C3B93B0FB</object-id>
        <label>Figure 3.</label>
        <caption>
          <p>Macroscopic view of the tumor mass.</p>
        </caption>
        <graphic xlink:href="foliamedica-66-2-e104433-g003.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_1040213.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1040213</uri>
        </graphic>
      </fig>
      <p><italic>The immunohistochemical analysis showed positive expression in neoplastic cells for TLE-1 (1F5), CD99 (O13), and Bcl2 (bcl-2/100/D5); negative expression in tumor cells for AE1/AE3 (PANCK), desmin (DE-R-11), SOX-10; negative expression in neoplastic cells but positive in the vascular network in the tumor mass for CD34 (QBEnd/10), Actin (SMA) (αSMA-1)</italic><bold><italic>(Fig. <xref ref-type="fig" rid="F4">4</xref>)</italic></bold> .</p>
      <fig id="F4" position="float" orientation="portrait">
        <object-id content-type="arpha">D82ED7EF-AF73-5162-9C20-2409766974CC</object-id>
        <label>Figure 4.</label>
        <caption>
          <p>Photomicrograph of immunohistochemical staining, showing positive expression of neoplastic cells for TLE (<bold>A</bold>), CD99 (<bold>B</bold>), Bcl-2 (<bold>C</bold>), positive expression in the vascular network for CD34 (<bold>D</bold>), and Actin (<bold>E</bold>).</p>
        </caption>
        <graphic xlink:href="foliamedica-66-2-e104433-g004.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_1040214.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1040214</uri>
        </graphic>
      </fig>
      <p>
        <italic>The immunoprofile of the neoplastic process in the lung favors synovial sarcoma (<abbrev xlink:title="synovial sarcoma" id="ABBRID0EUH">SS</abbrev>). Further fluorescent in situ hybridization (<abbrev xlink:title="Further fluorescent in situ hybridization" id="ABBRID0EYH">FISH</abbrev>) revealed monophasic fibrous (spindle cell) synovial sarcoma. According to the French Federation of Cancer Centers Sarcoma Group (<abbrev xlink:title="French Federation of Cancer Centers Sarcoma Group" id="ABBRID0E3H">FNCLCC</abbrev>) grading criteria, the tumor was graded as G3 (differentiation – score: 3; mitoses – score: 3; necrosis – score 2) and staged as T4N0M0R0.</italic>
      </p>
      <p>
        <italic>The postoperative period was uneventful. The patient was discharged from the hospital on postoperative day 7 and was referred to an oncology clinic. One year after surgery, the patient is in excellent condition and without PET/<abbrev xlink:title="computed tomography" id="ABBRID0EGAAC">CT</abbrev> data for recurrence.</italic>
      </p>
    </sec>
    <sec sec-type="Discussion" id="SECID0ELAAC">
      <title>Discussion</title>
      <p>Primary lung sarcomas are uncommon and aggressive malignancies with similar treatment and prognosis compared to other soft tissue sarcomas.<sup>[<xref ref-type="bibr" rid="B2">2</xref>]</sup> Lung sarcomas account for only 0.1%–0.5% of all primary pulmonary malignancies<sup>[<xref ref-type="bibr" rid="B3">3</xref>]</sup> with a 5-year overall survival rate of 50%<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup>. The most common variants of lung sarcoma are malignant fibrous histiocytoma and synovial sarcoma.<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup></p>
      <p>Synovial sarcoma is a mesenchymal spindle cell tumor that accounts for 5%–10% of all soft tissue sarcomas and is defined by a pathognomonic chromosomal translocation t(X;18)(p11.2;q11.2).<sup>[<xref ref-type="bibr" rid="B3">3</xref>]</sup> It arises from immature mesenchymal elements rather than from the synovium.<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup><abbrev xlink:title="synovial sarcoma" id="ABBRID0E3BAC">SS</abbrev> is most common in the extremities (more than 90%), especially near large joints, but the head and neck, lungs, heart, mediastinum, and the abdominal wall could also be primary localizations.</p>
      <p><abbrev xlink:title="primary pulmonary synovial sarcoma" id="ABBRID0ECCAC">PPSS</abbrev> usually affects young patients (median age between 31 and 50 years).<sup>[<xref ref-type="bibr" rid="B3">3</xref>]</sup> Patients with pulmonary synovial sarcoma usually report pleuritic chest pain (50.0%), cough (28.6%), palpable mass (7.1%), and dyspnea (7.1%).<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup> The differential diagnosis is very wide, but primary lung cancer should be excluded. The absence of significant lymphadenopathy in a young adult with a relatively large ovoid tumor favors <abbrev xlink:title="primary pulmonary synovial sarcoma" id="ABBRID0EUCAC">PPSS</abbrev> rather than primary lung cancer.<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup></p>
      <p><abbrev xlink:title="primary pulmonary synovial sarcoma" id="ABBRID0EADAC">PPSS</abbrev> presents on chest X-ray as a homogenous parenchymal formation with a well‑circumscribed rounded or lobulated border, a pleural mass, and partial or complete opacification of the hemithorax, with dimensions often more than 7 cm<sup>3</sup>. On <abbrev xlink:title="computed tomography" id="ABBRID0EGDAC">CT</abbrev> scan, these tumors show commonly heterogeneous enhancement with necrotic or cystic areas, vessels in the lesion, calcifications, tumor rupture, pleural/chest wall extension, and pleural effusion.<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup></p>
      <p><abbrev xlink:title="primary pulmonary synovial sarcoma" id="ABBRID0ESDAC">PPSS</abbrev> is aggressive, possibly due to its anatomic location and large tumor size generally resulting in insufficient resection and high proliferative activity.<sup>[<xref ref-type="bibr" rid="B6">6</xref>]</sup> Treatment of <abbrev xlink:title="primary pulmonary synovial sarcoma" id="ABBRID0E4DAC">PPSS</abbrev> includes surgical resection followed by chemotherapy or radiation therapy. Surgical treatment is the main option as there are no other standardized approaches. Adjuvant chemotherapy improves the time to local recurrence and recurrence-free survival and tends to improve overall survival.<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup> Due to the lack of preoperative morphological diagnosis and the giant size of the mass, we undertook open surgery through lateral muscle-sparing thoracotomy. A left lower lobectomy with atypical 5th segment resection was performed because of the lesion’s size and proximity to the large interlobar fissure.</p>
      <p>Primary pleuropulmonary <abbrev xlink:title="synovial sarcoma" id="ABBRID0EKEAC">SS</abbrev> seems to be with higher local aggressiveness than its soft-tissue counterpart, and this could be due to the difficulties in achieving wide surgical margins combined with a late presentation.<sup>[<xref ref-type="bibr" rid="B7">7</xref>]</sup> Patients with <abbrev xlink:title="primary pulmonary synovial sarcoma" id="ABBRID0EVEAC">PPSS</abbrev> have a poor prognosis, with a 5-year overall survival rate of 50%.<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup> Male gender, large tumor size, extensive tumor necrosis, neurovascular invasion, high histological grade, and mitotic rate are poor prognostic factors.<sup>[<xref ref-type="bibr" rid="B8">8</xref>]</sup></p>
    </sec>
    <sec sec-type="Conclusions" id="SECID0EGFAC">
      <title>Conclusions</title>
      <p><abbrev xlink:title="primary pulmonary synovial sarcoma" id="ABBRID0EMFAC">PPSS</abbrev> is a rare and aggressive neoplasm that primarily affects young people and has a poor prognosis. Establishing this diagnosis requires the exclusion of a wide number of other neoplasms and a wide work-up plan. The method of choice for treatment is mainly surgical with subsequent adjuvant chemo- or radiation therapy. Due to the risk of recurrence, these patients should be carefully monitored.</p>
    </sec>
    <sec sec-type="Ethical Approval" id="SECID0EQFAC">
      <title>Ethical Approval</title>
      <p>Ethical approval was not necessary as this is not a clinical study. The research meets all applicable standards concerning the ethics of experimentation and research integrity, and the following is being certified/declared true. No identifiable images or information were used.</p>
    </sec>
    <sec sec-type="Informed Consent" id="SECID0EVFAC">
      <title>Informed Consent</title>
      <p>Informed consent was obtained for all the procedures as a part of the patient’s hospital stay.</p>
    </sec>
    <sec sec-type="Consent for publication" id="SECID0E1FAC">
      <title>Consent for publication</title>
      <p>All authors read and agreed with the manuscript.</p>
    </sec>
    <sec sec-type="Availability of data and material" id="SECID0E6FAC">
      <title>Availability of data and material</title>
      <p>All figures and data are readily available.</p>
    </sec>
    <sec sec-type="Conflict of Interest" id="SECID0EEGAC">
      <title>Conflict of Interest</title>
      <p>None of the authors of this paper has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation xlink:type="simple">1. Roy P, Das A, Sarkar A, et al. A primary synovial sarcoma of lung. N Am J Med Sci 2012; 4(5):241–3.</mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation xlink:type="simple">2. Etienne-Mastroianni B, Falchero L, Chalabreysse L, et al. Primary sarcomas of the lung: a clinicopathologic study of 12 cases. Lung Cancer 2002; 38(3):283–9.</mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation xlink:type="simple">3. Panigrahi MK, Pradhan G, Sahoo N, et al. Primary pulmonary synovial sarcoma: A reappraisal. J Cancer Res Ther 2018; 14(3):481–9.</mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation xlink:type="simple">4. Dennison S, Weppler E, Giacoppe G. Primary pulmonary synovial sarcoma: a case report and review of current diagnostic and therapeutic standards. Oncologist 2004; 9(3):339–42.</mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation xlink:type="simple">5. Kim GH, Kim MY, Koo HJ, et al. Primary pulmonary synovial sarcoma in a tertiary referral center: clinical characteristics, CT, and 18F-FDG PET findings, with pathologic correlations. Medicine 2015; 94(34):e1392.</mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation xlink:type="simple">6. Okamoto S, Hisaoka M, Daa T, et al. Primary pulmonary synovial sarcoma: a clinicopathologic, immunohistochemical, and molecular study of 11 cases. Hum Pathol 2004; 35(7):850–6.</mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation xlink:type="simple">7. Essary LR, Vargas SO, Fletcher CD. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset. Cancer 2002; 94(2):459–69.</mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation xlink:type="simple">8. Chang C-C, Chang P-Y. Primary pulmonary synovial sarcoma. J Cancer Res Pract 2018; 5(1):24–6.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
